Continuous versus single-shot sciatic nerve block added to continuous femoral nerve block for analgesia and mobilisation after total knee arthroplasty

Continuous versus single-shot sciatic nerve block added to continuous femoral nerve block for analgesia and mobilisation after total knee arthroplasty - CoSinUS- Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00010152

Enrollment

Registered

2016-03-10

Start date

2016-03-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OPS: 5-822 Implantation of an endoprosthesis of the knee R52.9

Interventions

Group 1: Single-shot sciatic nerve block added to continuous femoral nerve block Single-Shot: 10ml 0,2% Naropin continuous: 5ml/h 0,2% Naropin Group 2: continuous sciatic nerve block added to continuo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patients scheduled for TKA under general anesthesia • Patients older than 18 years • Written informed consent • Preoperative dynamometer measurements possible

Exclusion criteria

Exclusion criteria: • Emergency surgery • BMI >40 • ASA 4-5 status • severe COPD (GOLD criteria = IV) • Preexisting lesions of lumbosacral plexus of the ipsilateral side. • Patients, unable to give their consent (need for bystanders) • Preexisting, relevant coagulopathy • Preexisting allergy of local anesthetics (amid type) • infections of the catheter insertion site) • patients unable to communicate in german language • patients scheduled for spinal anesthesia

Design outcomes

Primary

Measure	Time frame
Postoperative total Morphine consumption (in mg) up to 48h after the operation	—

Secondary

Measure	Time frame
1) Pain at rest and during movements in the operated knee as well as further body areas at the given time points: preoperative, PACU, Days 1,2 and 3 as well as during telephone follow-up-call. 2) Force measurements with a portable dynamometer (knee extension, foot flexion, foot extension) 3) Mobility (CAS, TUG test, MoSc, MRC-Score) 4) Anesthetic quality (Loss of temperature, loss of motor function) 5) Analgesic quality (NRS pain scale) at rest and during movements. 6) Patient satiscation (PPP33-questionaire) 7) Postoperative complications 8) Manual force measurements knee extension according to MRC (Janda score) from 0-5 9) Analysis of routine data (anesthesia chart, patient chart, other patient-related perioperative documents). The parameters were documented before catheter placement, postoperative during PACU stay as well as during the first 3 postoperative days during ward stay. Using a standardised questionnaire regarding late complications, the patient is called 2 weeks after the operation.	—

Measure

Time frame

1) Pain at rest and during movements in the operated knee as well as further body areas at the given time points: preoperative, PACU, Days 1,2 and 3 as well as during telephone follow-up-call. 2) Force measurements with a portable dynamometer (knee extension, foot flexion, foot extension) 3) Mobility (CAS, TUG test, MoSc, MRC-Score) 4) Anesthetic quality (Loss of temperature, loss of motor function) 5) Analgesic quality (NRS pain scale) at rest and during movements. 6) Patient satiscation (PPP33-questionaire) 7) Postoperative complications 8) Manual force measurements knee extension according to MRC (Janda score) from 0-5 9) Analysis of routine data (anesthesia chart, patient chart, other patient-related perioperative documents). The parameters were documented before catheter placement, postoperative during PACU stay as well as during the first 3 postoperative days during ward stay. Using a standardised questionnaire regarding late complications, the patient is called 2 weeks after the operation.

—

Countries

Germany

Contacts

Public ContactThomas Wiesmann

Universitätsklinikum MarburgKlinik für Anästhesie und Intensivtherapie

sek1anae@med.uni-marburg.de0049-64215865981

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 24, 2026